Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03370120 · ClinicalTrials.gov registry record · Phase 2
Study to Test the Safety and Efficacy of Padsevonil as Adjunctive Treatment of Focal-onset Seizures in Adult Subjects With Drug-resistant Epilepsy
A Phase 2 study, sponsored by UCB Biopharma SRL.
- Terminated
- Registry status
- Phase 2
- Development phase
- 406
- Enrollment target
NCT03370120 is a Phase 2 study that was terminated before completion, run by UCB Biopharma SRL. The registered enrollment target is 406 participants.
The verdict
NCT03370120, a Phase 2 study, was terminated before completion, sponsored by UCB Biopharma SRL.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 406 participants
- Enrollment target
Study Summary
The purpose of the study is to evaluate the long-term safety and tolerability of Padsevonil administered at individualized doses as adjunctive treatment for subjects with drug-resistant epilepsy.
Interventions
- DRUG Padsevonil
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 406 participants |
| Start Date | 2018-08-27 |
| Est. Completion | 2020-12-11 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03370120
The ClinicalTrials.gov registry entry for NCT03370120 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 406 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is UCB Biopharma SRL, which has 82 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Padsevonil is the first listed.
NCT03370120 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03370120 about?
NCT03370120 is a clinical study titled "Study to Test the Safety and Efficacy of Padsevonil as Adjunctive Treatment of Focal-onset Seizures in Adult Subjects With Drug-resistant Epilepsy". The purpose of the study is to evaluate the long-term safety and tolerability of Padsevonil administered at individualized doses as adjunctive treatment for subjects with drug-resistant epilepsy.
What is the current status of trial NCT03370120?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 406 participants. The study started on 2018-08-27. Estimated completion is 2020-12-11.
What interventions are being tested in trial NCT03370120?
The interventions under investigation include: Padsevonil (DRUG).
Who is sponsoring clinical trial NCT03370120?
This trial is sponsored by UCB Biopharma SRL, which has 82 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.